Story perspectives

Chinese Pharma Profits Surge Amid $60 Billion Licensing Boom

4/18/2026

Summary

Story summary

In 2025, over 70% of 169 reported Chinese pharmaceutical companies turned a profit.
Cross-border out-licensing deals surpassed $60 billion in early 2026, aided by supportive policies.
Innovent Biologics achieved its first annual profit.
Jiangsu Hengrui Pharmaceuticals reported a 22% rise in net profit, fueled by innovative drug sales.
Analysts see a selective phase favoring firms with robust pipelines and commercialization capabilities as the sector shifts toward high-quality development.

1 of 1

Story summary

In 2025, over 70% of 169 reported Chinese pharmaceutical companies turned a profit.
Cross-border out-licensing deals surpassed $60 billion in early 2026, aided by supportive policies.
Innovent Biologics achieved its first annual profit.
Jiangsu Hengrui Pharmaceuticals reported a 22% rise in net profit, fueled by innovative drug sales.
Analysts see a selective phase favoring firms with robust pipelines and commercialization capabilities as the sector shifts toward high-quality development.